



NDA 20-563/S-036

Eli Lilly and Company
Attention: Jeffrey L. Winn, D.D.S., R.Ph.
Senior Regulatory Research Scientist
US Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Winn:

Please refer to your supplemental new drug application dated September 17, 2002, received September 18, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Humalog (insulin lispro [rDNA origin]).

We acknowledge receipt of your submissions dated April 11, and July 16 and 25, 2003.

Your submission of July 16, 2003, constituted a complete response to our March 13, 2003, action letter.

This "Changes Being Effected" supplemental new drug application provides for revisions to the (1) package insert, (2) Information For The Patient for Humalog Pen, and (3) Disposable Insulin Delivery Device (Humalog Pen) User Manual to emphasize the need to prime Humalog Pen before each injection.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, and carton labels).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-563/S-036." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

- Enclosures:
1. Package insert (6.0 PA 9164-A FSAMP)
 2. INFORMATION FOR THE PATIENT (5.0 PA 9153-A FSAMP)
 3. Disposable Insulin Delivery Device (Insulin Pen) User Manual (5.0 PA 9113-A FSAMP)
 4. Carton label for Humalog Pen (SHMAQ 003 AM)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff

1/16/04 11:03:24 AM